Compounds are provided that, by way of their selective neurotransmitter
binding useful for the treatment of various neurological and
psychological disorders, e.g., ADHD. Such compounds are 4-phenyl
substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB,
IIIA or IIIC as set forth herein.